< Back to previous page
Organisation
Intellectual Property
Administrative Office
Main organisation:LRD Central Management
Lifecycle:1 Jan 2006 → Today
Keywords:eigendom, Technologie Transfer
Current researchers
1 - 1 of 1 results
- Patrick Chaltin (Member)
Projects
1 - 10 of 18
- Small molecule α-synuclein modulators for the treatment of Parkinson’s diseaseFrom1 Oct 2025 → TodayFunding: IOF - technology validation in lab
- Rationalizing interventions combating fetal reversion to cure colorectal cancerFrom1 Oct 2025 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts, FWO Strategic Basic Research (SBO)
- ATP13A2 agonists for Parkinson’s disease therapyFrom1 Mar 2024 → TodayFunding: IOF - technology validation in lab
- PHGDH-ASM: Phosphoglycerate dehydrogenase (PHGDH) activators as novel antiseizure medications (ASM) with dual mode of actionFrom1 Oct 2022 → 30 Sep 2024Funding: IOF - technology validation in lab
- VirusBank platform (state-of-the-art research platform for increased preparedness against viral epidemics and pandemics)From1 Jan 2022 → TodayFunding: Ministery of Economical Affairs
- Targeting transcription factor addiction in acute leukemia (TaTFAL)From1 Oct 2021 → 30 Sep 2025Funding: FWO Strategic Basic Research (SBO)
- Understanding the anti-cancer effects of new YAP/TAZ inhibitors to treat malignant mesotheliomaFrom1 Mar 2021 → 28 Feb 2025Funding: Foundations, funds and other with scientific goal
- MATATUM: Validation and druggability development of macrophage-specific targets in the tumor microenvironment.From1 Jan 2018 → 31 Dec 2021Funding: FWO Strategic Basic Research (SBO)
- Targeting ZEB pathways to tackle aggressive (colorectal) cancer (ZENTACC).From1 Jan 2018 → 31 Dec 2021Funding: FWO Strategic Basic Research (SBO)
- Towards a combined post-exposure prophylaxis and successful treatment of rabies in humansFrom1 Oct 2017 → 30 Sep 2020Funding: FWO research project (including WEAVE projects)
Publications
1 - 10 of 41
- Angiotensin II type 1 receptor blockers increase tolerance of cells to copper and cisplatin(2014)Published in: Microbial CellISSN: 2311-2638Issue: 11Volume: 1Pages: 352 - 364
- A novel irreversible TEAD inhibitor, SWTX-143, blocks Hippo pathway transcriptional output and causes tumor regression in preclinical mesothelioma models.(2023)Published in: MOLECULAR CANCER THERAPEUTICSISSN: 1535-7163Issue: 1Volume: 23Pages: OF1 - OF11
- Identification of novel FLT3 kinase inhibitors(2013)Published in: European Journal of Medicinal ChemistryISSN: 0223-5234Volume: 63Pages: 713 - 21
- Small molecule inhibitors of the LEDGF/p75 binding site of integrase (LEDGINs) block HIV replication and modulate integrase multimerization(2012)Published in: Antimicrobial Agents and ChemotherapyISSN: 0066-4804Issue: 8Volume: 56Pages: 4365 - 4374
- Interruption of lactate uptake by inhibiting mitochondrial pyruvate transport unravels direct antitumor and radiosensitizing effects(2018)Published in: Nature CommunicationsISSN: 2041-1723Issue: 1Volume: 9
- Repurposing as a means to increase the activity of amphotericin B and caspofungin against Candida albicans biofilms(2014)Published in: The Journal of Antimicrobial ChemotherapyISSN: 0305-7453Issue: 4Volume: 69Pages: 1035 - 1044
- Dual inhibition of SARS-CoV-2 and human rhinovirus with protease inhibitors in clinical development(2021)Published in: Antiviral ResISSN: 0166-3542Volume: 187
- Identification of Fungicidal 2,6-Disubstituted Quinolines with Activity against Candida Biofilms(2012)Published in: MoleculesISSN: 1420-3049Issue: 10Volume: 17Pages: 12243 - 12251
- Identification of drugs that restore primary cilium expression in cancer cells(2016)Published in: OncotargetISSN: 1949-2553Issue: 9Volume: 7Pages: 9975 - 92
- 2-(2-Oxo-morpholin-3-yl)-acetamide Derivatives as Broad-Spectrum Antifungal Agents(2015)Published in: Journal of Medicinal ChemistryISSN: 0022-2623Issue: 3Volume: 58Pages: 1502 - 1512